Market Place
Sourcing Support
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics
08 Sep 2021 //
BUSINESSWIRE
Catabasis rebrands post Duchenne disaster; Huadong joins Insilico in oncology
08 Sep 2021 //
ENDPTS
Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results
09 Aug 2021 //
BUSINESSWIRE
Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow
04 Aug 2021 //
BUSINESSWIRE
Catabasis Pharmaceuticals To Present At Ladenburg Thalmann
07 Jul 2021 //
BUSINESSWIRE
Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results
13 May 2021 //
BUSINESSWIRE
Catabasis snaps up HAE antibody in buyout; Gladstone, UCSF spearhead launch
30 Jan 2021 //
ENDPTS
Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.
29 Jan 2021 //
BUSINESSWIRE
Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.
29 Jan 2021 //
BIOSPACE
Catabasis Top-Line Results for the Ph3 PolarisDMD Trial of Edasalonexent
27 Oct 2020 //
BUSINESSWIRE
Catabasis Top-Line Results for the Ph3 PolarisDMD Trial of Edasalonexent
26 Oct 2020 //
BUSINESSWIRE
Catabasis Pharma to Present in Virtual 25th International Congress of WMS
23 Sep 2020 //
BUSINESSWIRE
Catabasis and Bill & Melinda Gates Medical Research Institute to Study CAT-5571
04 Aug 2020 //
BUSINESSWIRE
Catabasis to Present at Parent Project Muscular Dystrophy Virtual Conference
14 Jul 2020 //
BUSINESSWIRE
Catabasis Pharma Presents Edasalonexent, a Potential Foundational Therapy
12 May 2020 //
BIOSPACE
Catabasis Pharma Presents Edasalonexent, a Potential Foundational Therapy
12 May 2020 //
BUSINESSWIRE
Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association
17 Apr 2020 //
BIOSPACE
Catabasis Pharmaceuticals to Present Edasalonexent at the XVIII International
21 Feb 2020 //
BUSINESSWIRE
Catabasis Announces Pricing of $23 M Underwritten Public Offering
30 Jan 2020 //
BUSINESSWIRE
Catabasis Pharmaceuticals and Duchenne UK Announce Partnership
08 Jan 2020 //
BUSINESS WIRE
Catabasis Pharmaceuticals and Duchenne UK Announce Partnership
07 Jan 2020 //
BUSINESS WIRE
Catabasis Pharmaceuticals and Duchenne UK Announce Partnership
07 Jan 2020 //
BUSINESS WIRE
Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial
16 Dec 2019 //
BUSINESS WIRE
Catabasis Pharma Announces the Phase 3 PolarisDMD Trial of Edasalonexent
30 Sep 2019 //
BIOSPACE
Catabasis Pharmaceuticals Announces Pricing of $20 Million Public Offering
06 Feb 2019 //
BUSINESSWIRE
Catabasis Pharms Initiates Ph 3 Polaris DMD Clinical Trial for Edasalonexent
25 Sep 2018 //
BUSINESSWIRE
Catabasis Pharma Announces Plans for Edasalonexent Ph 3 POLARIS DMD Trial
09 Jul 2018 //
BUSINESSWIRE
Catabasis Pharma`s cholesterol drug fails mid-stage study
07 Jun 2016 //
REUTERS
EC grants Orphan Medicinal Product status to Catabasis Pharmaceutical CAT-1004
27 Oct 2015 //
PHARMABIZ
PPMD inks collaboration with Catabasis Pharma on CAT-1004 development to treat Duchenne
15 Dec 2014 //
PHARMABIZ
